BD
MCID: BHC003
MIFTS: 73

Behcet Syndrome (BD)

Categories: Bone diseases, Cardiovascular diseases, Eye diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Skin diseases

Aliases & Classifications for Behcet Syndrome

MalaCards integrated aliases for Behcet Syndrome:

Name: Behcet Syndrome 57 12 76 53 25 44 38 73
Behcet's Syndrome 12 53 25 6 43
Behcet's Disease 38 12 53 54 15
Behcet Disease 57 25 37 55
Behçet Disease 53 25 59
Adamantiades-Behcet Disease 12 25
Triple Symptom Complex 12 25
Bd 57 53
Behcet Triple Symptom Complex 25
Old Silk Route Disease 25
Malignant Aphthosis 25
Behcet Disease; Bd 57
Behçet's Syndrome 53
Behet's Syndrome 12
Behçet's Disease 53
Syndrome, Behcet 40
Behçet Syndrome 53

Characteristics:

Orphanet epidemiological data:

59
behçet disease
Inheritance: Multigenic/multifactorial; Prevalence: 1-5/10000 (Japan),>1/1000 (Turkey); Age of onset: Adolescent,Adult,Childhood; Age of death: adult;

OMIM:

57
Inheritance:
familial cases reported, but probably not mendelian


Classifications:



Summaries for Behcet Syndrome

NIH Rare Diseases : 53 Behçet disease is a chronic multisystem inflammatory disorder characterized by ulcers affecting the mouth and genitals, various skin lesions, and abnormalities affecting the eyes. In some people, the disease also results in arthritis (swollen, painful, stiff joints), skin problems, and inflammation of the digestive tract, brain, and spinal cord. Although it can happen at any age, symptoms generally begin when individuals are in their 20s or 30s. The disease is common in Japan, Turkey and Israel, and less common in the United States. The exact cause of Behçet disease is still unknown, but it is thought that it is an autoimmune disease, where the abnormal immune activity is triggered by exposure to an environmental agent (such as an infection) in people with a genetic predisposition to develop the disease. Research show that people with Behçet�??s disease, especially those of Middle Eastern and Asian descent, have an increased frequency of certain �??human leukocyte antigens�?� (HLAs), specifically HLA-B51, than the general population, which may increase the risk (predispose) to have the disease.  Treatment is symptomatic and supportive. Research is being conducted on the use of interferon-alpha and with agents which inhibit tumor necrosis factor (TNF) for the treatment of Behçet disease. Behçet disease is a lifelong disorder that comes and goes. Spontaneous remission over time is common for individuals with Behçet disease but permanent remission of symptoms has not been reported.

MalaCards based summary : Behcet Syndrome, also known as behcet's syndrome, is related to chlamydia and pyoderma, and has symptoms including angina pectoris, edema and pruritus. An important gene associated with Behcet Syndrome is MEFV (MEFV, Pyrin Innate Immunity Regulator), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Methylprednisolone and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and brain, and related phenotypes are seizures and ataxia

Disease Ontology : 12 A vasculitis that is characterized by an autoimmune mediated inflammation of the blood vessels throughout the body leading to ulcerations on the mouth and sometimes the genitals, notorious for causing hypopyon uveitis.

Genetics Home Reference : 25 Behçet disease is an inflammatory condition that affects many parts of the body. The health problems associated with Behçet disease result from widespread inflammation of blood vessels (vasculitis). This inflammation most commonly affects small blood vessels in the mouth, genitals, skin, and eyes.

MedlinePlus : 43 Behcet's syndrome is a disease that involves vasculitis, which is inflammation of the blood vessels. It causes problems in many parts of the body. The most common symptoms are Sores in the mouth Sores on the sex organs Other skin sores Swelling of parts of the eye Pain, swelling and stiffness of the joints More serious problems can include meningitis, blood clots, inflammation of the digestive system and blindness. Doctors aren't sure what causes Behcet's. It is rare in the United States, but is common in the Middle East and Asia. It mainly affects people in their 20s and 30s. Diagnosing Behcet's can take a long time, because symptoms may come and go, and it may take months or even years to have all of the symptoms. There is no cure. Treatment focuses on reducing pain and preventing serious problems. Most people can control symptoms with treatment. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

NINDS : 54 Behcet's disease is a rare, chronic inflammatory disorder. The cause of Behcet's disease is unknown, but current research suggests that both genetic and  environmental factors play a role.  Behcet's disease generally begins when individuals are in their 20s or 30s, although it can happen at any age. It tends to occur more often in men than in women. Symptoms of Behcet's disease include recurrent ulcers in the mouth (resembling canker sores) and on the genitals, and eye inflammation. The disorder may also cause various types of skin lesions, arthritis, bowel inflammation, meningitis (inflammation of the membranes of the brain and spinal cord), and cranial nerve palsies. Behcet's is a multi-system disease; it may involve all organs and affect the central nervous system, causing memory loss and impaired speech, balance, and movement. The effects of the disease may include blindness, stroke, swelling of the spinal cord, and intestinal complications. The disease is common in the Middle East, particularly in Turkey, and in Far Eastern nations such as Japan and Korean, but is less common in the United States.

Wikipedia : 76 Behçet''s disease (BD) is a type of inflammatory disorder which affects multiple parts of the body. The... more...

Description from OMIM: 109650

Related Diseases for Behcet Syndrome

Diseases related to Behcet Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 271)
# Related Disease Score Top Affiliating Genes
1 chlamydia 30.7 TNF TLR4 IL10 CRP
2 pyoderma 30.7 TNF PSTPIP1 NOD2 MEFV
3 pyoderma gangrenosum 30.7 TNF PSTPIP1 NOD2 MEFV
4 uveitis 30.6 TNF NOD2 IL10 HLA-B
5 meningitis 30.2 CRP IL10 TNF
6 aphthous stomatitis 30.2 TNF MEFV IL10 HLA-B
7 colitis 30.2 TNF TLR4 NOD2 IL23R IL10
8 vasculitis 30.2 TNF MEFV HLA-B CRP
9 familial mediterranean fever 30.2 CRP MEFV NOD2 PSTPIP1 TNF TNFRSF1A
10 crohn's disease 30.2 TNF NOD2 IL23R IL10 CRP
11 spondyloarthropathy 1 30.2 TNF TLR4 NOD2 HLA-B CRP
12 spondylitis 30.2 TNF NOD2 IL23R HLA-B ERAP1 CRP
13 bacterial meningitis 30.2 CRP IL10 TNF
14 endocarditis 30.1 CRP IL10 TNF
15 takayasu arteritis 30.1 CRP HLA-B TNF
16 binswanger's disease 11.4
17 subcortical arteriosclerotic encephalopathy 11.4
18 dementia - subcortical 11.4
19 intellectual disability - athetosis - microphthalmia 11.4
20 boomerang dysplasia 11.3
21 diamond-blackfan anemia 1 11.3
22 spondyloepiphyseal dysplasia-brachydactyly and distinctive speech 11.3
23 brody myopathy 11.3
24 diamond-blackfan anemia 11.2
25 behcet's syndrome arthropathy 11.1
26 brachydactyly, type e1 11.0
27 bipolar i disorder 11.0
28 bipolar disorder 10.5
29 psoriatic juvenile idiopathic arthritis 10.5 PSTPIP1 NOD2 MEFV
30 spondyloarthropathy 10.5 TNF IL10 HLA-B
31 pouchitis 10.4 TLR4 NOD2 IL10
32 intermittent hydrarthrosis 10.4 TNFRSF1A MEFV
33 inflammatory myopathy with abundant macrophages 10.4 TNFRSF1A MEFV
34 microscopic polyangiitis 10.4 TNF IL10 HLA-B
35 periodic fever, familial, autosomal dominant 10.4 TNFRSF1A TNF MEFV
36 orofacial granulomatosis 10.4 TNF NOD2 IL10
37 idiopathic achalasia 10.4 TNF IL23R IL10
38 spondylarthropathy 10.4 TNFRSF1A TNF TLR4 NOD2
39 autoimmune gastritis 10.4 TNF IL10 HLA-B
40 drug reaction with eosinophilia and systemic symptoms 10.4 TNF HLA-B CRP
41 blau syndrome 10.4 TNF NOD2 MEFV
42 uveal disease 10.4 TNF NOD2 IL10 HLA-B
43 post-transplant lymphoproliferative disease 10.4 TNFRSF1A TNF IL10
44 panuveitis 10.4 TNF IL10 HLA-B ERAP1
45 intermediate uveitis 10.4 TNF IL10 HLA-B
46 punctate inner choroidopathy 10.4 TNF IL10
47 relapsing fever 10.4 TNFRSF1A TNF MEFV CRP
48 q fever 10.4 TNF TLR4 NOD2 IL10
49 anterior uveitis 10.4 TNF TLR4 HLA-B
50 muckle-wells syndrome 10.4 TNFRSF1A MEFV CRP

Graphical network of the top 20 diseases related to Behcet Syndrome:



Diseases related to Behcet Syndrome

Symptoms & Phenotypes for Behcet Syndrome

Symptoms via clinical synopsis from OMIM:

57
Joints:
arthritis

Skin:
raynaud phenomenon
erythema nodosum-like eruptions
superficial thrombophlebitis
pustular skin lesions
hyperirritability

Mouth:
mouth ulcerations

Neuro:
brainstem syndrome
meningoencephalomyelitic syndrome
organic confusional state
schizoaffective disorder

Eyes:
uveitis
iritis
iridocyclitis
hypopyon
choreoretinitis

Hair:
alopecia areata

G U:
genital ulcerations
epididymitis


Clinical features from OMIM:

109650

Human phenotypes related to Behcet Syndrome:

59 32 (show top 50) (show all 81)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 seizures 59 32 occasional (7.5%) Occasional (29-5%) HP:0001250
2 ataxia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001251
3 gait disturbance 59 32 frequent (33%) Frequent (79-30%) HP:0001288
4 hyperreflexia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001347
5 nausea and vomiting 59 32 hallmark (90%) Very frequent (99-80%) HP:0002017
6 developmental regression 59 32 occasional (7.5%) Occasional (29-5%) HP:0002376
7 encephalitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002383
8 cataract 59 32 occasional (7.5%) Occasional (29-5%) HP:0000518
9 arthritis 59 32 hallmark (90%) Very frequent (99-80%) HP:0001369
10 splenomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0001744
11 increased intracranial pressure 59 32 occasional (7.5%) Occasional (29-5%) HP:0002516
12 aseptic necrosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0010885
13 malabsorption 59 32 occasional (7.5%) Occasional (29-5%) HP:0002024
14 blindness 59 32 occasional (7.5%) Occasional (29-5%) HP:0000618
15 renal insufficiency 59 32 occasional (7.5%) Occasional (29-5%) HP:0000083
16 retinopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0000488
17 photophobia 59 32 hallmark (90%) Very frequent (99-80%) HP:0000613
18 fever 59 32 hallmark (90%) Very frequent (99-80%) HP:0001945
19 cranial nerve paralysis 59 32 occasional (7.5%) Occasional (29-5%) HP:0006824
20 fatigue 59 32 hallmark (90%) Very frequent (99-80%) HP:0012378
21 subcutaneous nodule 59 32 hallmark (90%) Very frequent (99-80%) HP:0001482
22 arthralgia 59 32 frequent (33%) Frequent (79-30%) HP:0002829
23 myocardial infarction 59 32 occasional (7.5%) Occasional (29-5%) HP:0001658
24 abdominal pain 59 32 frequent (33%) Frequent (79-30%) HP:0002027
25 pulmonary embolism 59 32 occasional (7.5%) Occasional (29-5%) HP:0002204
26 abnormal blistering of the skin 59 32 frequent (33%) Frequent (79-30%) HP:0008066
27 irritability 59 32 occasional (7.5%) Occasional (29-5%) HP:0000737
28 weight loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0001824
29 acne 59 32 frequent (33%) Frequent (79-30%) HP:0001061
30 venous thrombosis 59 32 frequent (33%) Frequent (79-30%) HP:0004936
31 pancreatitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001733
32 anorexia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002039
33 migraine 59 32 hallmark (90%) Very frequent (99-80%) HP:0002076
34 memory impairment 59 32 occasional (7.5%) Occasional (29-5%) HP:0002354
35 cerebral ischemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002637
36 myalgia 59 32 hallmark (90%) Very frequent (99-80%) HP:0003326
37 paresthesia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003401
38 glomerulopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0100820
39 keratoconjunctivitis sicca 59 32 occasional (7.5%) Occasional (29-5%) HP:0001097
40 abnormal myocardium morphology 59 32 occasional (7.5%) Occasional (29-5%) HP:0001637
41 mitral regurgitation 59 32 occasional (7.5%) Occasional (29-5%) HP:0001653
42 vertigo 59 32 occasional (7.5%) Occasional (29-5%) HP:0002321
43 hemoptysis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002105
44 gastrointestinal hemorrhage 59 32 frequent (33%) Frequent (79-30%) HP:0002239
45 pericarditis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001701
46 endocarditis 59 32 occasional (7.5%) Occasional (29-5%) HP:0100584
47 meningitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0001287
48 vasculitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0002633
49 arterial thrombosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0004420
50 papule 59 32 hallmark (90%) Very frequent (99-80%) HP:0200034

UMLS symptoms related to Behcet Syndrome:


angina pectoris, edema, pruritus, chest pain, snoring, exanthema, halitosis, oral manifestations

GenomeRNAi Phenotypes related to Behcet Syndrome according to GeneCards Suite gene sharing:

26 (show top 50) (show all 64)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.21 IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-101 10.21 CCR1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.21 HLA-B
4 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.21 ADA2 CCR1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-106 10.21 ADA2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.21 ADA2 C4A
7 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.21 HLA-B
8 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.21 C4A CCR1 IL10 TLR4
9 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.21 TLR4
10 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.21 HLA-B
11 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.21 CCR1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.21 IL10
13 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.21 IL10 TLR4
14 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.21 ADA2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.21 IL10
16 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.21 C4A
17 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.21 CCR1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.21 IL10
19 Increased shRNA abundance (Z-score > 2) GR00366-A-156 10.21 HLA-B
20 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.21 ADA2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.21 C4A IL10
22 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.21 ADA2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.21 TLR4
24 Increased shRNA abundance (Z-score > 2) GR00366-A-174 10.21 NOD2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.21 NOD2
26 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.21 HLA-B
27 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.21 ADA2 C4A HLA-B NOD2
28 Increased shRNA abundance (Z-score > 2) GR00366-A-192 10.21 NOD2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.21 NOD2 CCR1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.21 CCR1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.21 IL10
32 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.21 ADA2
33 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.21 NOD2 IL10
34 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.21 IL10
35 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.21 IL10
36 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.21 HLA-B
37 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.21 NOD2 CCR1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.21 C4A NOD2
39 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.21 ADA2
40 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.21 ADA2
41 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.21 ADA2 IL10
42 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.21 C4A CCR1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.21 IL10
44 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.21 HLA-B
45 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.21 HLA-B
46 Increased shRNA abundance (Z-score > 2) GR00366-A-8 10.21 C4A
47 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10.21 ADA2 IL10
48 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.21 CCR1 IL10
49 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.21 IL10
50 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.21 ADA2

MGI Mouse Phenotypes related to Behcet Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.18 CCR1 ERAP1 FAS IL10 IL12A IL23R
2 homeostasis/metabolism MP:0005376 10.1 CCR1 CRP FAS IL10 IL12A IL23R
3 immune system MP:0005387 10.1 CCR1 CRP ERAP1 FAS IL10 IL12A
4 digestive/alimentary MP:0005381 10.01 CCR1 FAS IL10 IL23R NOD2 TLR4
5 liver/biliary system MP:0005370 9.7 CCR1 FAS IL10 MEFV TLR4 TNF
6 neoplasm MP:0002006 9.5 FAS IL10 IL12A IL23R TLR4 TNF
7 respiratory system MP:0005388 9.17 CCR1 FAS IL10 IL12A TLR4 TNF

Drugs & Therapeutics for Behcet Syndrome

Drugs for Behcet Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 83-43-2 6741
2
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-24-8 5755
3
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 302-25-0
4
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Not Applicable 2921-57-5
5
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4 67-73-2 6215
6
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Not Applicable 2920-86-7
7 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
8 Antineoplastic Agents, Hormonal Phase 4,Not Applicable
9 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
10 Hormone Antagonists Phase 4,Not Applicable
11 Prednisolone acetate Phase 4,Phase 3,Phase 2,Not Applicable
12 Neuroprotective Agents Phase 4,Not Applicable
13 glucocorticoids Phase 4,Not Applicable
14 Antiemetics Phase 4,Not Applicable
15 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
16 Hormones Phase 4,Not Applicable
17 Autonomic Agents Phase 4,Not Applicable
18 Protective Agents Phase 4,Not Applicable
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Not Applicable
20 Methylprednisolone acetate Phase 4,Phase 3,Phase 2,Not Applicable
21 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1
22 Omega 3 Fatty Acid Phase 4
23
Infliximab Approved Phase 3,Phase 1,Phase 2 170277-31-3
24
Adalimumab Approved Phase 3,Phase 2 331731-18-1 16219006
25
Apremilast Approved, Investigational Phase 3,Phase 2 608141-41-9 11561674
26
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
27
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
28 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
29 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Analgesics Phase 3,Phase 2,Not Applicable
33 Anti-Inflammatory Agents, Non-Steroidal Phase 3,Phase 2,Not Applicable
34 Analgesics, Non-Narcotic Phase 3,Phase 2,Not Applicable
35 Anti-Infective Agents Phase 3,Phase 2,Not Applicable
36 Anti-Bacterial Agents Phase 3,Phase 2
37 Cyclosporins Phase 3
38 Angiogenesis Modulating Agents Phase 3,Phase 2
39 Angiogenesis Inhibitors Phase 3,Phase 2
40 Antineoplastic Agents, Alkylating Phase 3,Phase 1
41 Alkylating Agents Phase 3,Phase 1
42 Antiviral Agents Phase 3,Phase 2
43 Antifungal Agents Phase 3
44 interferons Phase 3,Phase 2
45 Interferon-alpha Phase 3,Phase 2
46 Calcineurin Inhibitors Phase 3,Phase 1
47 Immunoglobulins Phase 3,Phase 2,Phase 1
48 Antibodies Phase 3,Phase 2,Phase 1
49 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
50
rituximab Approved Phase 2 174722-31-7 10201696

Interventional clinical trials:

(show top 50) (show all 76)
# Name Status NCT ID Phase Drugs
1 The Efficacy of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease Unknown status NCT01306955 Phase 4 methylorednisolone
2 Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease Unknown status NCT00720928 Phase 4 flucinolone acetonide
3 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
4 Saline vs. Lactated Ringers for Emergency Department IV Fluid Resuscitation Completed NCT03133767 Phase 4 Lactated Ringer Solution;Normal Saline 0.9% Infusion Solution Bag
5 A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease Completed NCT02505568 Phase 3 Infliximab
6 A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behcet's Disease Active, not recruiting NCT02307513 Phase 3 Apremilast (CC-10004);Placebo
7 Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis Terminated NCT02258867 Phase 3 Placebo;Gevokizumab
8 A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease Completed NCT01243671 Phase 3
9 Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions Completed NCT01532570 Phase 3 TA-650
10 Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease Not yet recruiting NCT03371095 Phase 3 Infliximab;Cyclophosphamide
11 Phase III Study in Refractory Behcet's Disease Completed NCT00995709 Phase 3 AIN457;AIN457;Placebo
12 Interferon α2a Versus Cyclosporine for Refractory Behçet`s Disease Uveitis Recruiting NCT03209219 Phase 3 Interferon Alfa-2A;Cyclosporine Pill
13 Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet`s Disease (INCYTOB) Completed NCT00167583 Phase 3 Cyclosporin A;Interferon-alpha2a
14 Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B) Terminated NCT01965145 Phase 3 Gevokizumab;Placebo
15 Efficacy of Humira in Behcet Patients With Arthritis Completed NCT01497717 Phase 3 Adalimumab (Humira)
16 Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis Terminated NCT01095250 Phase 3 AIN457;AIN457;AIN457;Placebo
17 Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors Recruiting NCT03221166 Phase 3 Thalidomide;Infliximab
18 Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X) Terminated NCT02375685 Phase 3
19 An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data Terminated NCT02258854 Phase 3 Dose 2 gevokizumab
20 Tocilizumab for the Treatment of Behcet's Syndrome Terminated NCT01693653 Phase 2 Tocilizumab
21 Colchicine Randomized Double-Blind Controlled Crossover Study in Behcet's Disease Completed NCT00700297 Phase 2 Colchicine;Placebo
22 A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease Completed NCT00866359 Phase 2 Apremilast (CC-10004);Placebo
23 Anti IL-18 (GSK1070806) in Behcet's Disease Not yet recruiting NCT03522662 Phase 2 GSK1070806
24 Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease Completed NCT00664599 Phase 2 Rituximab;Cytotoxic Combination
25 Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease Recruiting NCT02648581 Phase 2 Subcutaneous Ustekinumab
26 Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study Completed NCT02620618 Phase 1, Phase 2 Intravitreal Infliximab
27 1 Year Canakinumab Treatment in Behcet's Disease Patients With Neurologic or Vascular Involvement Recruiting NCT02756650 Phase 2 drug administration
28 Low Dose Interferon Alpha Treatment for Oral Ulcers of Behcet's Disease Completed NCT00483184 Phase 2
29 HAT in Eye Complications of Behcet's Disease Completed NCT00001865 Phase 2 Daclizumab
30 Tocilizumab for the Treatment of Refractory Behcet's Uveitis Recruiting NCT03554161 Phase 2
31 A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease Withdrawn NCT01211977 Phase 1, Phase 2 XOMA 052
32 Anakinra for Behcet s Disease Completed NCT01441076 Phase 1, Phase 2 Anakinra
33 Ilaris (Canakinumab) in the Schnitzler Syndrome Completed NCT01245127 Phase 2 Ilaris
34 Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Subjects With Moderate-To-Severe Plaque-Type Psoriasis Completed NCT01988103 Phase 2 Apremilast;Apremilast;Placebo
35 Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis Recruiting NCT02929251 Phase 2 Anakinra;Tocilizumab;Adalimumab
36 Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases Recruiting NCT01988506 Phase 2 Interleukin 2
37 Stem Cell Transplantation for the Treatment of Knee Osteoarthritis Unknown status NCT00550524 Phase 1
38 Stem Cell Transplantation in Ocular Lesions of Behcet's Disease Terminated NCT00550498 Phase 1
39 Hematopoietic Stem Cell Support in Vasculitis Terminated NCT00278512 Phase 1 Cyclophosphamide;ATG (rabbit);G-CSF;Campath-1h;Fludarabine;Tacrolimus;Mesna
40 Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease Unknown status NCT00931957 Not Applicable Etanercept, Methotrexate, Prednisolone
41 The Serum Angiotensin Converting Enzyme and Lysozyme Levels in Patients Non-infectious and Infectious Uveitis Unknown status NCT02627209 Not Applicable
42 Causes of Visual Loss in Retinal Disease Unknown status NCT01613963 Immunosuppressive Agents
43 Behçet's Disease Overall Damage Index Recruiting NCT03803462
44 Evaluation of Fibromyalgia With Disease Activity and Clinical Findings in Women With Behçet's Disease Recruiting NCT03543709
45 Frequency of Fibromyalgia in Behcet Disease Recruiting NCT03514056
46 Psychological Symptoms in Patients With Behcet's Disease by SCL90-R Completed NCT00699985
47 Assessment of Disease Activity in Behcet by Complete Blood Count Not yet recruiting NCT03747354 Not Applicable
48 Assessment of Central Sensitization, Neuropathic Pain, Sleep Quality and Daily Life Activities in Behcet's Disease Recruiting NCT03531385
49 Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation) Completed NCT01960790
50 A Prospective, Mono-Country and Multi-center Study to Observe Safety and Effectiveness of Adalimumab in KoREan Intestinal Behcet's Disease(BD) Patients Active, not recruiting NCT02687828

Search NIH Clinical Center for Behcet Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Behcet Syndrome cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Behcet Syndrome:
Bone marrow-derived stem cells for treatment of ocular lesions Behcet's disease
Embryonic/Adult Cultured Cells Related to Behcet Syndrome:
Bone marrow-derived stem cells PMIDs: 21199472 23773637

Cochrane evidence based reviews: behcet syndrome

Genetic Tests for Behcet Syndrome

Anatomical Context for Behcet Syndrome

MalaCards organs/tissues related to Behcet Syndrome:

41
Eye, Skin, Brain, Spinal Cord, Bone, Lung, Testes

Publications for Behcet Syndrome

Articles related to Behcet Syndrome:

(show top 50) (show all 722)
# Title Authors Year
1
Nervous system involvement in Behçet's syndrome. ( 30407226 )
2019
2
Treatment of deep vein thrombosis in a patient with Behcet syndrome using ultrasound-accelerated catheter-directed thrombolysis. ( 30398005 )
2018
3
Preoperative Misdiagnosis of Intestinal Behçet's Syndrome as Crohn's Disease Based on Superficial Colonoscopic Biopsies: Case Report and Systematic Review. ( 30151660 )
2018
4
Primary optic neuropathy in Behçet's syndrome. ( 29985083 )
2018
5
Adalimumab efficacy for venous thrombosis in typical sites in Behçet's syndrome. ( 30537215 )
2018
6
Adalimumab for Venous Thrombosis in Behçet's Syndrome: Further Questions need to be answered. ( 30548210 )
2018
7
Outcomes of Patients with Behçet's Syndrome after Pulmonary Endarterectomy. ( 28810271 )
2018
8
Is Warfarin Indicated in Behcet's Syndrome Associated with Thrombosis? Reflections on Treatment and Death of a Patient. ( 29271390 )
2018
9
2018 update of the EULAR recommendations for the management of Behçet's syndrome. ( 29625968 )
2018
10
Hemoptysis in Behçet's syndrome: from bedside to bench? ( 29736629 )
2018
11
Genetics and epigenetics pathogenesis of Behçet's syndrome. ( 29779484 )
2018
12
Behçet's Syndrome and Nervous System Involvement. ( 29789966 )
2018
13
Management of skin, mucosa and joint involvement of Behçet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet's syndrome. ( 29954598 )
2018
14
Surgical Treatment of Pulmonary Complications in Behçet's Syndrome. ( 30031945 )
2018
15
New Insights into Behçet's Syndrome Metabolic Reprogramming: Citrate Pathway Dysregulation. ( 30050389 )
2018
16
Management of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendations. ( 30107448 )
2018
17
Efficacy of the anti-IL 17 secukinumab in refractory Behçet's syndrome: A preliminary study. ( 30213443 )
2018
18
Behcet's Syndrome: Fear Not the Unknown. ( 30236452 )
2018
19
Behçet's syndrome as a tool to dissect the mechanisms of thrombo-inflammation: clinical and pathogenetic aspects. ( 30472725 )
2018
20
Vascular Behçet's syndrome: an update. ( 30499073 )
2018
21
Concurrent presence of buccal mucosal and ophthalmologic lesions in Behcet's syndrome. ( 30510645 )
2018
22
Triggering agents and microbiome as environmental factors on Behçet's syndrome. ( 30523495 )
2018
23
Exacerbation of Behçet's syndrome and familial Mediterranean fever with menstruation. ( 29148415 )
2017
24
Infliximab for uveitis of Behçet's syndrome: a trend for earlier initiation. ( 29148418 )
2017
25
Behcet's syndrome in nonendemic regions. ( 27684358 )
2017
26
Neurological complications of Behçet's syndrome. ( 28283819 )
2017
27
Adherence to guidelines for the treatment of Behçet's syndrome in New York and Amsterdam. ( 28406760 )
2017
28
Behçet's syndrome and health-related quality of life: influence of symptoms, lifestyle and employment status. ( 28598773 )
2017
29
Behçet's syndrome: providing integrated care. ( 28860798 )
2017
30
To immunosuppress or not: Behcet's syndrome presenting as an eosinophilic pleural effusion. ( 28869232 )
2017
31
Qualitative study: the experience and impact of living with Behcet's syndrome. ( 28934765 )
2017
32
One year in review 2017: Behçet's syndrome. ( 28980900 )
2017
33
Pure red aplasia induced by sodium valproate in a patient with Behçet's syndrome. ( 29148419 )
2017
34
A Patient with Neuro-Behçet's Syndrome Presenting with Peripheral Nerve Involvement. ( 29321715 )
2017
35
Serum Vitamin B12, Homocysteine and Methylmalonic Acid Levels in Patients With Parenchymal Neuro-Behçet's Syndrome. ( 30375556 )
2017
36
Delayed Vasospasm after Aneurysmal Subarachnoid Hemorrhage in Behcet Syndrome. ( 27114963 )
2016
37
Ocular Manifestation of Non-Parenchymal Neuro-Behçet Syndrome. ( 27116518 )
2016
38
Development of de novo major involvement during follow-up in Behçet's syndrome. ( 25750177 )
2016
39
Management of Behçet's syndrome. ( 26555450 )
2016
40
Validation and reliability of a Behcet's Syndrome Activity Scale in Korea. ( 26767871 )
2016
41
Behçet's syndrome with gangrenous bilateral lower limbs. ( 26837940 )
2016
42
Fatigue in patients with Behcet's syndrome: relationship with quality of life, depression, anxiety, disability and disease activity. ( 26913703 )
2016
43
To anticoagulate or not to anticoagulate vascular thrombosis in Behçet's syndrome: an enduring question. ( 26967193 )
2016
44
Characteristics, Treatment, and Long-Term Outcome of Gastrointestinal Involvement in Behcet's Syndrome: A Strobe-Compliant Observational Study From a Dedicated Multidisciplinary Center. ( 27100417 )
2016
45
New therapeutic solutions for Behçet's syndrome. ( 27163156 )
2016
46
Vein inflammation and ultrasound in Behçet's syndrome. ( 27371697 )
2016
47
Bronchial artery enlargement may be the cause of recurrent haemoptysis in Behçet's syndrome patients with pulmonary artery involvement during follow-up. ( 27791952 )
2016
48
Behçet's syndrome in the 2000s: "Where is the wisdom we have lost in knowledge?" ( 27791957 )
2016
49
One year in review 2016: Behçet's syndrome. ( 27791958 )
2016
50
Highlights of the 17th International Conference on Behçet's syndrome. ( 27791959 )
2016

Variations for Behcet Syndrome

ClinVar genetic disease variations for Behcet Syndrome:

6 (show all 34)
# Gene Variation Type Significance SNP ID Assembly Location
1 NOD2 NM_022162.2(NOD2): c.2446G> A single nucleotide variant Pathogenic rs886040969 GRCh37 Chromosome 16, 50746268: 50746268
2 NOD2 NM_022162.2(NOD2): c.2446G> A single nucleotide variant Pathogenic rs886040969 GRCh38 Chromosome 16, 50712357: 50712357
3 TNFRSF1A NM_001065.3(TNFRSF1A): c.463C> T (p.His155Tyr) single nucleotide variant Pathogenic rs886039866 GRCh37 Chromosome 12, 6442542: 6442542
4 TNFRSF1A NM_001065.3(TNFRSF1A): c.463C> T (p.His155Tyr) single nucleotide variant Pathogenic rs886039866 GRCh38 Chromosome 12, 6333376: 6333376
5 NOD2 NM_022162.2(NOD2): c.2197G> T (p.Val733Leu) single nucleotide variant Pathogenic rs746055479 GRCh38 Chromosome 16, 50712108: 50712108
6 NOD2 NM_022162.2(NOD2): c.2197G> T (p.Val733Leu) single nucleotide variant Pathogenic rs746055479 GRCh37 Chromosome 16, 50746019: 50746019
7 NOD2 NM_022162.2(NOD2): c.241C> G (p.Leu81Val) single nucleotide variant Pathogenic rs34936594 GRCh37 Chromosome 16, 50733566: 50733566
8 NOD2 NM_022162.2(NOD2): c.241C> G (p.Leu81Val) single nucleotide variant Pathogenic rs34936594 GRCh38 Chromosome 16, 50699655: 50699655
9 ADA2 NM_001282225.1(ADA2): c.145C> T (p.Arg49Trp) single nucleotide variant Uncertain significance rs199614299 GRCh38 Chromosome 22, 17209533: 17209533
10 ADA2 NM_001282225.1(ADA2): c.145C> T (p.Arg49Trp) single nucleotide variant Uncertain significance rs199614299 GRCh37 Chromosome 22, 17690423: 17690423
11 ADA2 NM_001282225.1(ADA2): c.927G> A (p.Met309Ile) single nucleotide variant Likely benign rs146597836 GRCh38 Chromosome 22, 17189987: 17189987
12 ADA2 NM_001282225.1(ADA2): c.927G> A (p.Met309Ile) single nucleotide variant Likely benign rs146597836 GRCh37 Chromosome 22, 17670877: 17670877
13 ADA2 NM_001282225.1(ADA2): c.740C> T (p.Ala247Val) single nucleotide variant Pathogenic rs750868279 GRCh38 Chromosome 22, 17203576: 17203576
14 ADA2 NM_001282225.1(ADA2): c.740C> T (p.Ala247Val) single nucleotide variant Pathogenic rs750868279 GRCh37 Chromosome 22, 17684466: 17684466
15 MEFV NM_000243.2(MEFV): c.1211A> G (p.His404Arg) single nucleotide variant Pathogenic rs755659290 GRCh38 Chromosome 16, 3249480: 3249480
16 MEFV NM_000243.2(MEFV): c.1211A> G (p.His404Arg) single nucleotide variant Pathogenic rs755659290 GRCh37 Chromosome 16, 3299480: 3299480
17 MEFV NM_000243.2(MEFV): c.1099C> G (p.Leu367Val) single nucleotide variant Pathogenic rs1057519328 GRCh38 Chromosome 16, 3249592: 3249592
18 MEFV NM_000243.2(MEFV): c.1099C> G (p.Leu367Val) single nucleotide variant Pathogenic rs1057519328 GRCh37 Chromosome 16, 3299592: 3299592
19 TNFRSF1A NM_001065.3(TNFRSF1A): c.935G> A (p.Arg312Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs200900510 GRCh38 Chromosome 12, 6329900: 6329900
20 TNFRSF1A NM_001065.3(TNFRSF1A): c.596T> C (p.Ile199Thr) single nucleotide variant Uncertain significance rs104895247 GRCh38 Chromosome 12, 6330882: 6330882
21 TNFRSF1A NM_001065.3(TNFRSF1A): c.596T> C (p.Ile199Thr) single nucleotide variant Uncertain significance rs104895247 GRCh37 Chromosome 12, 6440048: 6440048
22 MEFV NM_000243.2(MEFV): c.332G> A (p.Gly111Glu) single nucleotide variant Pathogenic rs751454741 GRCh38 Chromosome 16, 3254736: 3254736
23 MEFV NM_000243.2(MEFV): c.332G> A (p.Gly111Glu) single nucleotide variant Pathogenic rs751454741 GRCh37 Chromosome 16, 3304736: 3304736
24 ADA2 NM_001282225.1(ADA2): c.1045G> A (p.Val349Ile) single nucleotide variant Benign rs74317375 GRCh38 Chromosome 22, 17188375: 17188375
25 ADA2 NM_001282225.1(ADA2): c.1045G> A (p.Val349Ile) single nucleotide variant Benign rs74317375 GRCh37 Chromosome 22, 17669265: 17669265
26 TNFRSF1A NM_001065.3(TNFRSF1A): c.935G> A (p.Arg312Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs200900510 GRCh37 Chromosome 12, 6439066: 6439066
27 PSTPIP1 NM_003978.4(PSTPIP1): c.203C> T (p.Thr68Met) single nucleotide variant Likely benign rs201872851 GRCh37 Chromosome 15, 77310863: 77310863
28 PSTPIP1 NM_003978.4(PSTPIP1): c.203C> T (p.Thr68Met) single nucleotide variant Likely benign rs201872851 GRCh38 Chromosome 15, 77018522: 77018522
29 PSTPIP1 NM_003978.4(PSTPIP1): c.865G> C (p.Asp289His) single nucleotide variant Pathogenic rs774164456 GRCh37 Chromosome 15, 77325229: 77325229
30 PSTPIP1 NM_003978.4(PSTPIP1): c.865G> C (p.Asp289His) single nucleotide variant Pathogenic rs774164456 GRCh38 Chromosome 15, 77032888: 77032888
31 PSTPIP1 NM_003978.4(PSTPIP1): c.364G> A (p.Val122Ile) single nucleotide variant Uncertain significance rs886041107 GRCh38 Chromosome 15, 77027861: 77027861
32 PSTPIP1 NM_003978.4(PSTPIP1): c.364G> A (p.Val122Ile) single nucleotide variant Uncertain significance rs886041107 GRCh37 Chromosome 15, 77320202: 77320202
33 NOD2 NM_022162.2(NOD2): c.1045C> T (p.Leu349Phe) single nucleotide variant Pathogenic rs752615209 GRCh37 Chromosome 16, 50744867: 50744867
34 NOD2 NM_022162.2(NOD2): c.1045C> T (p.Leu349Phe) single nucleotide variant Pathogenic rs752615209 GRCh38 Chromosome 16, 50710956: 50710956

Copy number variations for Behcet Syndrome from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 241985 8 6835170 6856724 Copy number DEFA1 Behcet''s disease

Expression for Behcet Syndrome

Search GEO for disease gene expression data for Behcet Syndrome.

Pathways for Behcet Syndrome

Pathways related to Behcet Syndrome according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.79 ADA2 C4A CCR1 CRP ERAP1 HLA-B
2
Show member pathways
13.34 CCR1 FAS IL10 IL12A IL23R STAT4
3
Show member pathways
13.32 CCR1 HLA-B IL10 IL12A IL23R NOD2
4
Show member pathways
13.26 CCR1 FAS IL10 IL12A IL23R TNF
5
Show member pathways
13 CCR1 FAS HLA-B STAT4 TLR4 TNF
6
Show member pathways
12.77 C4A FAS HLA-B IL10 IL12A KLRC4
7
Show member pathways
12.75 FAS HLA-B IL12A TLR4 TNF TNFRSF1A
8
Show member pathways
12.66 FAS IL10 IL12A MEFV NOD2 PSTPIP1
9
Show member pathways
12.58 FAS IL12A TLR4 TNF TNFRSF1A
10 12.54 FAS IL10 STAT4 TNF TNFRSF1A
11
Show member pathways
12.49 IL10 IL12A IL23R NOD2 STAT4 TLR4
12
Show member pathways
12.38 FAS IL10 PSTPIP1 TNF
13
Show member pathways
12.37 CCR1 IL10 IL12A IL23R STAT4
14
Show member pathways
12.19 IL10 IL12A TLR4 TNF TNFRSF1A
15
Show member pathways
12.15 FAS STAT4 TLR4 TNF TNFRSF1A
16 12.1 IL10 IL12A NOD2 TLR4 TNF TNFRSF1A
17 11.96 IL10 IL12A IL23R TNF
18 11.93 FAS NOD2 TNF TNFRSF1A
19 11.85 IL10 IL12A TLR4 TNF
20 11.83 TLR4 TNF TNFRSF1A
21 11.82 CCR1 IL10 IL12A IL23R STAT4
22 11.75 IL10 IL12A IL23R TNF
23 11.71 IL10 IL12A TNF
24 11.69 IL10 IL12A TNF
25 11.69 TLR4 TNF TNFRSF1A
26 11.56 IL12A TLR4 TNF
27 11.55 TLR4 TNF TNFRSF1A
28
Show member pathways
11.55 IL10 IL12A IL23R STAT4 TLR4 TNF
29 11.54 C4A IL10 IL12A TLR4 TNF
30 11.52 FAS TNF TNFRSF1A
31 11.49 IL12A TLR4 TNF
32 11.49 IL10 IL12A TLR4 TNF
33 11.45 FAS TNF TNFRSF1A
34 11.34 IL10 TLR4 TNF
35 11.3 FAS IL10 IL12A TNF
36 11.1 NOD2 TNF TNFRSF1A
37 10.71 CCR1 IL10 IL12A TNF TNFRSF1A

GO Terms for Behcet Syndrome

Cellular components related to Behcet Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 ADA2 C4A CRP ERAP1 IL10 IL12A
2 extracellular region GO:0005576 9.61 ADA2 C4A CRP ERAP1 FAS IL10
3 cell surface GO:0009986 9.17 FAS HLA-B IL12A NOD2 TLR4 TNF

Biological processes related to Behcet Syndrome according to GeneCards Suite gene sharing:

(show all 49)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.98 CCR1 NOD2 TLR4 TNF
2 innate immune response GO:0045087 9.91 C4A CRP IL23R MEFV NOD2 PSTPIP1
3 negative regulation of inflammatory response GO:0050728 9.88 IL10 MEFV TNFRSF1A
4 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.88 NOD2 TLR4 TNF TNFRSF1A
5 defense response to bacterium GO:0042742 9.88 IL10 NOD2 TLR4 TNF TNFRSF1A
6 defense response to Gram-positive bacterium GO:0050830 9.87 CRP IL12A TNF
7 immune response GO:0006955 9.87 CCR1 FAS HLA-B IL10 IL12A TLR4
8 positive regulation of JNK cascade GO:0046330 9.86 NOD2 TLR4 TNF
9 response to lipopolysaccharide GO:0032496 9.86 IL10 IL12A IL23R TLR4
10 cellular response to mechanical stimulus GO:0071260 9.85 FAS TLR4 TNFRSF1A
11 positive regulation of inflammatory response GO:0050729 9.85 TLR4 TNF TNFRSF1A
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.82 IL12A IL23R TNFRSF1A
13 regulation of inflammatory response GO:0050727 9.82 NOD2 TLR4 TNF
14 apoptotic signaling pathway GO:0097190 9.8 FAS TLR4 TNF
15 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.8 TLR4 TNF TNFRSF1A
16 cellular response to lipopolysaccharide GO:0071222 9.8 IL10 IL12A NOD2 TLR4 TNF
17 positive regulation of interleukin-6 production GO:0032755 9.79 NOD2 TLR4 TNF
18 immune system process GO:0002376 9.76 C4A ERAP1 HLA-B IL23R MEFV NOD2
19 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.74 NOD2 TLR4 TNF
20 interleukin-12-mediated signaling pathway GO:0035722 9.72 IL10 IL12A STAT4
21 extrinsic apoptotic signaling pathway GO:0097191 9.71 FAS IL12A TNF
22 negative regulation of growth of symbiont in host GO:0044130 9.7 IL10 TNF
23 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.7 IL10 TNF
24 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.7 NOD2 TLR4
25 positive regulation of interleukin-17 production GO:0032740 9.69 IL23R NOD2
26 interferon-gamma production GO:0032609 9.69 IL12A TLR4
27 negative regulation of interleukin-12 production GO:0032695 9.69 IL10 MEFV
28 negative regulation of interleukin-6 production GO:0032715 9.69 IL10 TLR4 TNF
29 negative regulation of interleukin-17 production GO:0032700 9.68 IL12A TLR4
30 interleukin-35-mediated signaling pathway GO:0070757 9.68 IL12A STAT4
31 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.67 TLR4 TNF
32 positive regulation of interleukin-8 production GO:0032757 9.67 NOD2 TLR4 TNF
33 interleukin-23-mediated signaling pathway GO:0038155 9.66 IL23R STAT4
34 negative regulation of lipid storage GO:0010888 9.66 CRP TNF
35 positive regulation of ceramide biosynthetic process GO:2000304 9.65 TNF TNFRSF1A
36 positive regulation of lymphocyte proliferation GO:0050671 9.65 IL12A TLR4
37 death-inducing signaling complex assembly GO:0071550 9.64 TNF TNFRSF1A
38 endothelial cell apoptotic process GO:0072577 9.63 IL10 TNF
39 positive regulation of T cell mediated cytotoxicity GO:0001916 9.63 HLA-B IL12A IL23R
40 positive regulation of MHC class II biosynthetic process GO:0045348 9.61 IL10 TLR4
41 regulation of establishment of endothelial barrier GO:1903140 9.61 TNF TNFRSF1A
42 positive regulation of osteoclast differentiation GO:0045672 9.61 CCR1 IL23R TNF
43 necroptotic signaling pathway GO:0097527 9.6 FAS TNF
44 negative regulation of cytokine secretion involved in immune response GO:0002740 9.59 IL10 TNF
45 positive regulation of NK T cell activation GO:0051135 9.58 IL12A IL23R
46 positive regulation of interferon-gamma production GO:0032729 9.56 IL12A IL23R TLR4 TNF
47 receptor biosynthetic process GO:0032800 9.52 IL10 TNF
48 cytokine-mediated signaling pathway GO:0019221 9.5 CCR1 IL10 IL12A IL23R STAT4 TNF
49 inflammatory response GO:0006954 9.32 C4A CCR1 CRP IL10 IL23R MEFV

Molecular functions related to Behcet Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.5 CRP FAS MEFV PSTPIP1 STAT4 TLR4
2 complement component C1q binding GO:0001849 9.16 C4A CRP
3 interleukin-12 receptor binding GO:0005143 8.62 IL12A IL23R

Sources for Behcet Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....